Brief: Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months Of Follow-Up, With No Additional Doses, In Immunocompetent Participants
29/10/2024 11:24
Oct 29 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD PHASE 3 LONG-TERM EXPLORATORY CLINICAL EFFICACY
DATA
SHOWS PEMGARDA™ (PEMIVIBART) PROVIDED SUBSTANTIAL PROTECTION
FROM SYMPTOMATIC COVID-19 VERSUS PLACEBO OVER SIX MONTHS OF
FOLLOW-UP, WITH NO ADDITIONAL DOSES, IN IMMUNOCOMPETENT
PARTICIPANTS
Source text: ID:nGNX6j0w5S
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview